Get 25% discount on our yearly plans! Subscribe now
| Market Cap | 3.03M |
| Total Shares Outstanding | |
| Book Value | -0.99 |
| PE Ratio | - |
| PS Ratio | - |
| PB Ratio | 0.48 |
| Forward PE Ratio | - |
| ROIC | - |
| Return on Aseets | -91.42 |
| Return on Equity | -362.29 |
| Dividend | - |
| Dividend Yield | - |
| Total Assets | 1.56M |
| Total Liability | 2.47M |
| Assets-to-Libability Ratio | 0.63 |
| Total Current Assets | 1.56M |
| Total Current Liability | 2.47M |
| Current Ratio | 0.63 |
| Quick Ratio | - |
| Debt to Equity Ratio | - |
| Net Income | -12.06M |
| EPS | -13.25 |
| EBITA | -12.03M |
| Gross Profit | - |
| Gross Profit Margin | - |
| Operating Margin | - |
| Net Profit Margin | - |
| 5 Days MA | |
| 10 Days MA | |
| 20 Days MA | |
| 50 Days MA | |
| 200 Days MA |
| 52 Weeks High | |
| 52 Weeks low | |
| All Time High |
| RSI | |
| MACD |
| Shares Float | |
| Shares Short |
| % Short | |
| % Insider | 2.572% |
| % Institutions | 0.037% |
Virpax Pharmaceuticals Inc (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Exchange: NASDAQ
IPO Date: 2/17/2021
Sector: Healthcare
Industry: Biotechnology
Employees: 2
Address: 1055 Westlakes Drive, Berwyn, PA, United States, 19312
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | Totals | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 1.56K | 304.162 | 2.59K | 3.13K | 9.63K | 13.04K | 15.95K | 18.49K | 19.67K | 23.64K | 185.05K | ||||||||||||
| Current Assets | 1.56K | 304.162 | 2.59K | 3.13K | 9.63K | 13.04K | 15.95K | 18.49K | 19.67K | 23.64K | 185.74K | ||||||||||||
| Cash And Short Term Investments | 1.51K | 17.229 | 1.87K | 1.87K | 9.14K | 12.15K | 14.80K | 16.99K | 19.00K | 20.56K | 165.67K | ||||||||||||
| Net Receivables | - | - | - | - | - | - | - | - | - | - | 751.388 | ||||||||||||
| Inventory | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Other Current Assets | 42.557 | 286.933 | 719.88 | 1.26K | 486.833 | 885.394 | 1.15K | 1.51K | 521.611 | 2.59K | 15.82K | ||||||||||||
| Non Current Assets | - | - | - | - | - | - | - | - | - | - | 568.728 | ||||||||||||
| Property Plant Equipment | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Long Term Investments | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Non Currrent Assets Other | - | - | - | - | - | - | - | - | - | - | 568.728 | ||||||||||||
| Liabilities | 2.47K | 2.36K | 5.39K | 4.34K | 7.69K | 6.53K | 3.65K | 3.29K | 3.09K | 4.21K | 60.67K | ||||||||||||
| Current Liabilities | 2.47K | 2.36K | 5.39K | 4.34K | 7.69K | 6.53K | 3.65K | 3.29K | 3.09K | 4.21K | 70.97K | ||||||||||||
| Accounts Payable | - | - | 75.399 | 13.275 | 18.457 | 33.192 | 0.07606 | 0.04525 | 1.09K | 4.21K | 17.88K | ||||||||||||
| Short Long Term Debt | - | - | - | - | - | - | - | - | - | - | 2.45K | ||||||||||||
| Other Current Liabilities | 2.47K | 2.36K | 5.31K | 4.33K | 7.68K | 6.50K | 3.65K | 3.29K | 2.00K | 4.21K | 51.70K | ||||||||||||
| Non Current Liabilities | - | - | - | - | - | - | - | - | 1.09K | 4.21K | 8.22K | ||||||||||||
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Other Liabilities | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Stockholder Equity | -913.76 | -2.05K | -2.79K | -1.21K | 1.93K | 6.51K | 12.30K | 15.20K | 16.58K | 19.43K | 130.83K | ||||||||||||
| Preferred Stock Equity | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Liabilities And Stockholders Equity | 1.56K | 304.162 | 2.59K | 3.13K | 9.63K | 13.04K | 15.95K | 18.49K | 19.67K | 23.64K | 177.73K | ||||||||||||
| Common Equity | - | - | - | - | - | - | - | - | - | - | 0.09204999999999999 | ||||||||||||
| Retained Earnings | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Totals | 12.72K | 6.23K | 23.72K | 24.34K | 63.53K | 78.26K | 87.05K | 99.06K | 105.50K | 134.53K | 156.19K | 179.14K | 209.71257 | 219.98877999999993 | 66.40K | 12.67K | -297.89800000000014 | 9.83K | 4.76K | 4.76K | 5.80K | 1.07M | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | Totals | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | 1.56M | 9.63K | 19.67K | 39.57K | 465.406 | 46.719 | 61.5 | 1.63M | |
| Current Assets | 1.56M | 9.63K | 19.67K | 39.57K | 73.069 | 46.719 | 61.5 | 1.62M | |
| Cash And Short Term Investments | 1.51M | 9.14K | 19.00K | 36.84K | 54.796 | 41.536 | 48.37 | 1.58M | |
| Net Receivables | - | - | - | - | - | 1.388 | - | 1.388 | |
| Inventory | - | - | - | - | - | 3.328 | - | 3.328 | |
| Other Current Assets | 42.56K | 486.833 | 678.365 | 2.73K | 18.273 | 0.467 | 13.13 | 46.48K | |
| Non Current Assets | - | - | - | - | 392.337 | - | - | 392.337 | |
| Non Currrent Assets Other | - | - | - | - | 392.337 | - | - | 392.337 | |
| Liabilities | 2.47M | 7.69K | 3.09K | 2.09K | 4.68K | 2.78K | 1.25K | 2.49M | |
| Current Liabilities | 2.47M | 7.69K | 3.09K | 2.09K | 3.66K | 2.78K | 1.25K | 2.49M | |
| Accounts Payable | - | 0.01846 | 37.644 | 19.841 | 22.107 | 0.0035 | 6.553 | 86.16695999999999 | |
| Short Long Term Debt | - | - | - | - | 543.99 | 1.26K | 500 | 2.31K | |
| Other Current Liabilities | 2.47M | 7.69K | 3.06K | 2.06K | 3.08K | 1.51K | 746.759 | 2.49M | |
| Non Current Liabilities | - | - | 1.09459 | - | 1.02K | 1.26K | - | 2.29K | |
| Stockholder Equity | -913.76K | 1.93K | 16.58K | 37.48K | -4.22K | -2.73K | -1.19K | -865.90K | |
| Liabilities And Stockholders Equity | 1.56M | 9.63K | 19.67K | 39.57K | 465.406 | 46.719 | 61.5 | 1.63M | |
| Common Equity | - | - | - | - | 0.031 | 0.03 | 0.029 | 0.09 | |
| Totals | 12.72M | 63.53K | 104.56K | 202.03K | 10.66K | 7.06K | 2.82K | 13.11M | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | Totals | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | ||
| Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | ||
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | ||
| Operating Expenses | 5.90K | 5.12K | -3.24M | 3.25M | 2.31K | 4.20K | 4.20K | 1.66K | 1.23K | 615.865 | 35.62K | ||
| Selling General Administrative | 2.65K | 1.78K | -1.55M | 1.55M | 1.99K | 2.90K | 2.90K | 810.674 | 1.06K | 448.985 | 20.25K | ||
| Research Development | 3.26K | 3.34K | -1.69M | 1.70M | 316.565 | 1.29K | 1.29K | 851.78 | 168.673 | 166.88 | 15.36K | ||
| Other Operating Expenses | - | 5.12K | - | - | 2.31K | 4.20K | 4.20K | 1.66K | 1.23K | - | 19.38K | ||
| Operating Income | -5.90K | -5.12K | -4.12K | -3.25K | -2.31K | -4.20K | -686.877 | -1.66K | -1.23K | -615.865 | -29.76K | ||
| Net Interest Income | - | - | 0.818 | -28.892 | -34.049 | -30.699 | -18.334 | -45.709 | -43.261 | -40.63 | -277.463 | ||
| Interest Income | - | - | - | - | - | - | - | - | - | - | - | ||
| Interest Expense | - | - | 28.95K | -28.89K | 34.049 | 147.934 | 147.934 | 45.709 | 43.261 | 40.63 | 554.9970000000011 | ||
| Other Income Expense Net | 19.374 | -13.183 | 3.21M | -3.21M | -37.882 | 4 | -3.65K | -45.709 | 39.261 | - | -5.99K | ||
| Income Before Tax | -5.88K | -5.14K | 3.21M | -3.22M | -2.34K | -4.34K | -4.34K | -1.71K | -1.27K | -656.495 | -36.09K | ||
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | ||
| NetIncome | -5.88K | -5.14K | 3.21M | -3.22M | -2.34K | -4.34K | -4.34K | -1.71K | -1.27K | -656.495 | -36.09K | ||
| NetIncome Applicable To Common Shares | -5.88K | -5.14K | -4.12K | -3.22K | -2.34K | -2.38K | -705.211 | -1.71K | -963.14 | -656.495 | -27.81K | ||
| Ebit | -5.90K | -5.12K | -4.12K | -3.25K | -2.31K | -2.35K | -4.34K | -1.66K | - | -615.865 | -30.33K | ||
| Basic EPS | - | -0.44 | - | -0.27 | -0.53 | -0.47 | -0.6 | -0.22 | -0.54 | -0.41 | -3.7000000000000006 | ||
| Totals | -17.63K | -10.30K | 3.16M | -3.18M | -4.76K | -4.89K | -5.35K | -3.51K | -1.00K | -1.97K | -1.40K | -75.19K | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | Totals | |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | |
| Cost Of Revenue | - | - | - | - | - | |
| Gross Profit | - | - | - | - | - | |
| Operating Expenses | 12.03K | 4.20K | 3.18K | 2.63K | 22.03K | |
| Selling General Administrative | 7.19K | 2.90K | 2.56K | 1.48K | 14.13K | |
| Research Development | 4.84K | 1.29K | 622.741 | 1.14K | 7.90K | |
| Other Operating Expenses | - | 4.20K | 3.18K | 2.63K | 10.00K | |
| Operating Income | -12.03K | -4.20K | -3.18K | -2.63K | -22.03K | |
| Net Interest Income | -92.822 | -147.934 | -124.644 | -14.976 | -380.376 | |
| Interest Income | - | - | - | - | - | |
| Interest Expense | 92.822 | 147.934 | 124.644 | 14.976 | 380.376 | |
| Other Income Expense Net | -30.563 | -143.934 | -124.644 | -14.976 | -314.11699999999996 | |
| Income Before Tax | -12.06K | -4.34K | -3.31K | -2.64K | -22.34K | |
| Tax Provision | - | - | - | - | - | |
| NetIncome | -12.06K | -4.34K | -3.31K | -2.64K | -22.34K | |
| NetIncome Applicable To Common Shares | -12.06K | -4.34K | -3.31K | -2.64K | -22.34K | |
| Ebit | -12.03K | -4.34K | -3.18K | -2.63K | -22.17K | |
| Basic EPS | -1.28 | -1.78 | -1.07 | -0.27 | -4.4 | |
| Totals | -36.20K | -9.11K | -6.86K | -5.31K | -57.49K | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | Totals | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash From Operating Activities | -2.87K | -4.47K | -1.64K | -7.73K | -3.01K | -2.65K | -2.18K | -2.01K | -1.57K | -5.50K | -60.76K | ||||||||||||
| Net Income | -3.39K | -2.01K | -3.45K | -3.22K | -4.56K | -5.99K | -3.11K | -1.52K | -2.99K | -7.64K | -73.98K | ||||||||||||
| Depreciation | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Extraordinary Items | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Change Receivables | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Change To Inventory | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Change To Liabilities | - | - | - | - | - | - | - | - | - | - | 1.21K | ||||||||||||
| Change To Net Income | - | - | - | - | - | - | - | - | - | - | 2.92K | ||||||||||||
| ChangeToOperatingActivities | - | - | - | - | - | - | - | - | - | - | -3.22K | ||||||||||||
| Cash flows From Investing Activities | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Capital Expenditures | - | -0.003 | -0.003 | - | - | - | - | - | - | - | -0.006 | ||||||||||||
| Other Cashflows From Investing Activities | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Cash From Financing Activities | 4.37K | 2.62K | 1.65K | 453.951 | - | - | - | - | - | - | 77.25K | ||||||||||||
| Net Borrowings | - | - | - | - | - | - | - | - | - | - | -3.39K | ||||||||||||
| Sale Purchase Of Stock | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Other Cashflows From Financing Activities | - | 2.62K | 1.65K | 453.951 | - | - | - | - | - | - | 33.04K | ||||||||||||
| Cash And Cash Equivalents Changes | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||
| Totals | -1.89K | -1.24K | -1.80K | -10.04K | -7.57K | -8.65K | -5.30K | -3.53K | -4.55K | -13.14K | -9.47K | -12.09K | 3.23M | -3.17M | 7.97K | -7.95K | -4.53K | -1.35K | -321.0390000000001 | -34.62199999999998 | -296.458 | -26.93K | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | Totals | |
|---|---|---|---|---|---|---|---|---|---|
| Cash From Operating Activities | -16.71M | -9.85K | -17.85K | -14.54K | -1.38K | -1.13K | -1.80K | -16.76M | |
| Net Income | -12.07M | -15.19K | -21.65K | -12.06K | -4.34K | -3.31K | -2.64K | -12.13M | |
| Depreciation | - | - | - | - | - | - | - | - | |
| Extraordinary Items | - | - | - | - | - | - | - | - | |
| Change Receivables | - | - | - | - | - | - | - | - | |
| Change To Inventory | - | - | - | - | - | - | - | - | |
| Change To Liabilities | - | - | - | -686.776 | 1.34K | 923.942 | 454.501 | 2.03K | |
| Change To Net Income | - | - | - | 912.418 | 1.63K | 1.24K | 399.931 | 4.18K | |
| ChangeToOperatingActivities | - | - | - | -2.71K | -13.09 | 7.947 | -13.13 | -2.73K | |
| Cash flows From Investing Activities | - | - | - | - | - | - | - | - | |
| Capital Expenditures | - | - | - | - | - | - | - | - | |
| Other Cashflows From Investing Activities | - | - | - | - | - | - | - | - | |
| Cash From Financing Activities | 9.08M | - | - | 51.33K | 1.40K | 1.13K | 1.67K | 9.14M | |
| Net Borrowings | - | - | - | -1.50K | 72.1 | 500 | 554.766 | -376.898 | |
| Sale Purchase Of Stock | - | - | - | - | - | - | - | - | |
| Dividends Paid | - | - | - | - | - | - | - | - | |
| Other Cashflows From Financing Activities | 9.08M | - | - | -5.19K | -50.88 | 500 | 554.766 | 9.07M | |
| Cash And Cash Equivalents Changes | - | - | - | - | - | - | - | - | |
| Totals | -10.62M | -25.04K | -39.50K | 15.55K | -1.35K | -138.66800000000057 | -814.9740000000003 | -10.67M | |
